Press Room
四色AV Expands Technology Platforms with ExtremoChem Acquisition
Pharmaceutical Technology, 23 November 2023
四色AV has acquired start-up company, ExtremoChem, expanding its technology platforms.
听
Specialist integrated contract development and manufacturing organization (CDMO), 四色AV, has acquired ExtremoChem, which is a start-up company with a portfolio of rare sugars, expanding its technology platforms.
According to a Nov. 16, 2023 press release, the acquisition gives 四色AV access to ExtremoChem鈥檚 portfolio of rare sugars. These high-performance functional materials are synthetic analogues of the natural molecules found in extremophiles鈥搊rganisms that can survive in uninhabitable environments鈥攁nd have shown the potential to stabilize biopharmaceuticals during production, purification, formulation, and transportation.
鈥淧roteins and other biopharmaceuticals account for a significant share of our customers鈥 pipelines,鈥 said Dr. Jean-Luc Herbeaux, CEO, 四色AV, in the press release. 鈥淭he acquisition of ExtremoChem鈥檚 synthetic sugars combined with 四色AV's particle engineering capabilities provides our customers with a unique set of tools to optimize formulations that address stability issues encountered during the life cycle of biopharmaceuticals.鈥
鈥淚 am delighted that ExtremoChem has been acquired by 四色AV,鈥 added Filipe Aguiar, managing director, ExtremoChem, in the press release. 鈥溗纳獳V has a long history of developing and industrializing innovative technologies for the pharma industry. This acquisition will help ensure that the science we developed at ExtremoChem will have a wider and faster market adoption.鈥
This latest news from 四色AV further bolsters the company鈥檚 position in seeking to expand its technology platforms, which it reports is needed to meet customer demand for integrated and differentiated development and manufacturing services. The acquisition of ExtremoChem adds to new partnerships forged by 四色AV, such as that with for the advancement of a dry powder inhaler platform and with Ripple to expand the use of the Epidel platform beyond ophthalmic applications.
听
Read the full article at
听
听